Fresenius Medical (FMS) news

Fresenius SE - anticipated book gain in low to mid double-digit mln EUR range will be reflected in Fresenius Group's Q3 2026 results

Fresenius SE & Co. KGaA is expected to report a book gain in the low to mid double-digit million EUR range in its Q3 2026 results. This gain, which will be reflected in the company’s quarterly earnings, follows a year of strong operational performance across its core businesses. In Q2 2026, the…

Fresenius SE - net proceeds will reduce group net debt and be available for future investment

Fresenius SE & Co. KGaA reported that net proceeds from recent financial activities will reduce group net debt and be available for future investment, aligning with its ongoing deleveraging strategy. As of December 31, 2025, the company’s leverage ratio stood at 2.7× (net debt to EBITDA), a…

Fresenius: amount about 2.9% of Fresenius Medical Care capital

Fitch revises Fresenius SE's outlook to positive; affirms rating at 'BBB-'

Fitch Ratings has revised the credit outlook for Fresenius SE to positive while affirming its long-term issuer default rating (IDR) at IDR at 'BBB-' . This upgrade reflects the company’s improved financial performance and structural resilience, according to Fitch analysts. The positive outlook…

Fresenius: holder rights attached to shares remain unchanged

Fresenius Medical Care AG & Co. KGaA has announced plans to propose a change in its legal structure from a KGaA (Kommanditgesellschaft auf Aktien) to a German stock corporation (Aktiengesellschaft). This proposed transition aims to streamline governance and enhance decision-making efficiency.…